More efficient mobilisation of peripheral blood stem cells with HiDAC + AMSA + G-CSF than with mini-ICE + G-CSF in patients with AML

Bone Marrow Transplantation

Volumn 32, Issue 12, 2003, Pages 1119-1124

  Höglund, Martin ^a   Brune, M ^b   Sallerfors, B ^c   Ahlgren, T ^c   Billstrom R ^c   Hedenus, M ^d   Markevarn B ^e   Nilsson, B ^c   Simonsson, B ^a   Stockelberg, D ^b   Wahlin, A ^e  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d Central Hospital   (Sweden)

^e UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

AML; Chemotherapy; G CSF; Haematopoietic stem cell mobilisation

Indexed keywords

AMSACRINE; CD34 ANTIGEN; CYTARABINE; ETOPOSIDE; IDARUBICIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CELL COUNT; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HIGH RISK POPULATION; HUMAN; INTERMETHOD COMPARISON; LEUKAPHERESIS; LEUKOCYTE COUNT; MALE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; STEM CELL MOBILIZATION; THROMBOCYTE COUNT;

ACUTE DISEASE; ADULT; AGED; AMSACRINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD CELL COUNT; CASPASE 14; CASPASES; COHORT STUDIES; COMBINED MODALITY THERAPY; CYTARABINE; ETOPOSIDE; FEMALE; FILGRASTIM; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; IDARUBICIN; LEUKAPHERESIS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 0347917174     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704294     Document Type: Article

References (30)

1. Gorin NC. Autologous stem cell transplantation in acute myelocytic leukemia. Blood 1998; 92: 1073-1090.
2. Kimby E, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in acute myeloid leukaemia. Acta Oncol 2001; 40: 231-252.
3. Burnett A. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. Lancet 1998; 351: 700-708.
4. Zittoun RA, Mandelli F, Willemze R et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 1995; 332: 217-223.
5. Reiffers J, Labopin M, Sanz M et al. Autologous blood cell vs marrow transplantation for acute myeloid leukemia in complete remission: an EBMT retrospective analysis. Bone Marrow Transplant 2000; 25: 1115-1119.
6. Schmitz N, Linch D, Dreger P et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow tranplantation in lymphoma patients. Lancet 1996; 347: 353-357.
7. Lowenberg B, van Putten WL, Ferrant A et al. Peripheral blood progenitor cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia. Stem Cells 1997; 15 (Suppl 1): 177-180, discussion 81.
8. Schlenk RF, Dohner H, Pforsich M et al. Successful collection of peripheral blood progenitor cells in patients with acute myeloid leukaemia following early consolidation therapy with granulocyte colony-stimulating factor-supported high-dose cytarabine and mitoxantrone. Br J Haematol 1997; 99: 386-393.
9. Visani G, Lemoli R, Tosi P et al. Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells. Bone Marrow Transplant 1999; 24: 467-472.
10. Stewart DA, Guo D, Morris D et al. Superior autologous blood stem cell mobilization from dose-intensive cyclophosphamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimens. Bone Marrow Transplant 1999; 23: 111-117.
11. Visani G, Lemoli RM, Tosi P et al. Fludarabine-containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukaemia patients. Br J Haematol 1999; 105: 775-779.
12. Demirer T, Bensinger WI, Buckner CD. Peripheral blood stem cell mobilization for high-dose chemotherapy. J Hematother 1999; 8: 103-113.
13. Castagnola C, Alessandrino EP, Lunghi M et al. Consolidation treatment with autologous peripheral blood progenitor cell transplantation in acute myeloid leukemia: a single center experience. Ann Hematol 2001; 80: 267-271.
14. Carella AM, Dejana A, Lerma E et al. In vivo mobilization of karyotypically normal peripheral blood progenitor cells in high-risk MDS, secondary or therapy-related acute myelogenous leukaemia. Br J Haematol 1996; 95: 127-130.
15. Carella AM, Lerma E, Celesti L et al. Effective mobilization of Philadelphia-chromosome-negative cells in chronic myelogenous leukaemia patients using a less intensive regimen. Br J Haematol 1998; 100: 445-448.
16. Grimwade D, Walker H, Oliver F et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322-2333.
17. + cell analysis: technical recommendations for progenitor estimation in leukapheresis from multiple myeloma patients (for the laboratories associated to the Nordic myeloma study group). J Hematother 1995; 4: 21-28.
18. Weaver CH, Hazelton B, Birch R et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961-3969.
19. Tricot G, Jagannath S, Vesole D et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588-596.
20. Shimazaki C, Yamagata N, Tatsumi T et al. Mobilization of peripheral blood progenitor cells by high-dose Ara C, VP-16 and recombinant human granulocyte colony-stimulating factor: factors affecting progenitor cell yields. Bone Marrow Transplant 1995; 15: 763-767.
21. Russell NH, McQuaker G, Stainer C et al. Stem cell mobilisation in lymphoproliferative diseases. Bone Marrow Transplant 1998; 22: 935-940.
22. Reiffers J. Peripheral blood stem cell transplantation in acute myeloid leukemia: the experience of the Bordeaux Group. Stem Cells 1995; 13 (Suppl 3): 19-22.
23. Ketterer N, Salles G, Moullet I et al. Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. Br J Haematol 1998; 103: 235-242.
24. Carral A, de la Rubia J, Martin G et al. Factors influencing the collection of peripheral blood stem cells in patients with acute myeloblastic leukemia and non-myeloid malignancies. Leuk Res 2003; 27: 5-12.
25. Roberts AW, DeLuca E, Begley CG et al. Broad inter-individual variations in circulating progenitor cell numbers induced by granulocyte colony-stimulating factor therapy. Stem Cells 1995; 13: 512-516.
26. Linker CA, Ries CA, Damon LE et al. Autologous stem cell transplantation for acute myeloid leukemia in first remission. Biol Blood Marrow Transplant 2000; 6: 50-57.
27. Schiller G, Wong S, Lowe T et al. Transplantation of IL-2-mobilized autologous peripheral blood progenitor cells for adults with acute myelogenous leukemia in first remission. Leukemia 2001; 15: 757-763.
28. Balduzzi A, Perseghin P, Dassi M et al. Peripheral blood stem cell collection in children with acute leukemia: effectiveness of the 'DIAVE' mobilizing regimen. Bone Marrow Transplant 2002; 30: 413-416.
29. Haynes A, Hunter A, McQuaker G et al. Engraftment characteristics of peripheral blood stem cells mobilised with cyclophosphamide and the delayed addition of G-CSF. Bone Marrow Transplant 1995; 16: 359-363.
30. Benet I, Prosper BF, Marugan I et al. Mobilization of peripheral blood progenitor cells (PBPC) in patients undergoing chemotherapy followed by autologous peripheral blood stem cell transplant (SCT) for high risk breast cancer (HRBC). Bone Marrow Transplant 1999; 23: 1101-1107.